Protective effect of bromelain on some metabolic enzyme activities in tyloxapol‐induced hyperlipidemic rats.
Saved in:
| Title: | Protective effect of bromelain on some metabolic enzyme activities in tyloxapol‐induced hyperlipidemic rats. |
|---|---|
| Authors: | Sulumer, Ayşe Nurseli1 (AUTHOR), Palabıyık, Esra1 (AUTHOR), Avcı, Bahri1 (AUTHOR), Uguz, Handan1 (AUTHOR), Demir, Yeliz2 (AUTHOR) yelizdemir2116@gmail.com, Serhat Özaslan, Muhammet2 (AUTHOR), Aşkın, Hakan1 (AUTHOR) |
| Source: | Biotechnology & Applied Biochemistry. Feb2024, Vol. 71 Issue 1, p17-27. 11p. |
| Subjects: | Bromelin, Acetylcholinesterase, Blood lipids, Aldose reductase, Enzymes, Glutathione transferase, Glutathione reductase |
| Abstract: | Elevation of one or more plasma lipids, such as phospholipids, cholesterol esters, cholesterol, and triglycerides, is known as hyperlipidemia. In humans and experimental animals, bromelain, the primary active ingredient isolated from pineapple stems, has several positive effects, including anti‐tumor growth, anticoagulation, and anti‐inflammation. Hence, the purpose of this study was to determine the possible protective impact of bromelain on some metabolic enzymes (paraoxonase‐1, glutathione S‐transferase, glutathione reductase, sorbitol dehydrogenase [SDH], aldose reductase [AR], butyrylcholinesterase [BChE], and acetylcholinesterase [AChE]), activity in the heart, kidney, and liver of rats with tyloxapol‐induced hyperlipidemia. Rats were divided into three groups: control group, HL‐control group (tyloxapol 400 mg/kg, i.p. administered group), and HL+bromelain (group receiving bromelain 250 mg/kg/o.d. prior to administration of tyloxapol 400 mg/kg, i.p.). BChE, SDH, and AR enzyme activities were significantly increased in all tissues in HL‐control compared to the control, whereas the activity of other studied enzymes was significantly decreased. Bromelain had a regulatory effect on all tissues and enzyme activities. In conclusion, these results prove that bromelain is a new mediator that decreases hyperlipidemia. [ABSTRACT FROM AUTHOR] |
| Copyright of Biotechnology & Applied Biochemistry is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Engineering Source |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Elevation of one or more plasma lipids, such as phospholipids, cholesterol esters, cholesterol, and triglycerides, is known as hyperlipidemia. In humans and experimental animals, bromelain, the primary active ingredient isolated from pineapple stems, has several positive effects, including anti‐tumor growth, anticoagulation, and anti‐inflammation. Hence, the purpose of this study was to determine the possible protective impact of bromelain on some metabolic enzymes (paraoxonase‐1, glutathione S‐transferase, glutathione reductase, sorbitol dehydrogenase [SDH], aldose reductase [AR], butyrylcholinesterase [BChE], and acetylcholinesterase [AChE]), activity in the heart, kidney, and liver of rats with tyloxapol‐induced hyperlipidemia. Rats were divided into three groups: control group, HL‐control group (tyloxapol 400 mg/kg, i.p. administered group), and HL+bromelain (group receiving bromelain 250 mg/kg/o.d. prior to administration of tyloxapol 400 mg/kg, i.p.). BChE, SDH, and AR enzyme activities were significantly increased in all tissues in HL‐control compared to the control, whereas the activity of other studied enzymes was significantly decreased. Bromelain had a regulatory effect on all tissues and enzyme activities. In conclusion, these results prove that bromelain is a new mediator that decreases hyperlipidemia. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 08854513 |
| DOI: | 10.1002/bab.2517 |
